In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories

mRNA: The Future Beyond COVID Vaccines

Messenger RNA (mRNA) prophylactic vaccines have made major breakthroughs in 2020 and 2021 with both the Pfizer/BioNTech and Moderna COVID-19 vaccines gaining approval in more than 150 countries. These mRNA COVID vaccines have been developed much faster and with superior clinical profiles when compared to other more conventional modalities.

Commercial Strategies Biologics

Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target

Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.

Denmark C-Suite Speaks Commercial Strategies

How To Develop A Patient-First Strategy For CGT Commercialization

Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene treatments are no different. As Amerisource Bergen’s Lung-I Cheng tells In Vivo, creating a patient-first blueprint is the best place to start.

Gene Therapy Market Access Strategy

Latest Articles

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Seagen Deal Ticks The Big Three For Pfizer: Revenues, Pipeline, Platform

Pfizer expects Seagen’s portfolio of approved drugs and development pipeline to add $10bn in annual revenue by 2030.  

Business Strategies Biosimilars

VC Playbook: Finding Early-Stage Financing When Money Is Scarce

Early-stage companies need to be more flexible on the financing terms they are willing to accept and in finding ways to gather evidence to support the impact of their products or services.

VC Playbook Business Strategies

Snapshot: February Highlights

A selection of articles you may have missed from February 2023, during which In Vivo focused on the art of dealmaking and its impacts on the life sciences as a whole.

Commercial Deals

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Eyeing Early Chronic Disease Detection Through AI-Based Retinal Scans

South Korean start-up Mediwhale is using AI-guided retinal scans to predict the risk of eye, cardiovascular and kidney diseases. The company has moved ahead of a small pack of competitors and gained regulatory approval and market access in eight territories through a focus on gathering strong evidence to support algorithms.

South Korea Asia Pacific

Podcast: OxSonics Hopes To Use Ultrasound To Enhance Drug Efficacy – Without Reformulation

In this one-off podcast, reporter Barnaby Pickering speaks Jérôme Marzinski and Dr Christian Coviello, the CEO and CTO, respectively, of OxSonics, a UK-based start-up which is working on an ultrasound-based technology that has been designed to enhance the potency of oncological drugs.

Commercial Clinical Trials

Would You Like Chips With That? High-Tech Alternatives Could Replace Animal Testing

The FDA Modernization Act 2.0 should make it easier for companies to gain regulatory authorization using non-traditional testing methods, like organs-on-a-chip. But biopharma will need to make the leap into technology to help build knowledge and data if the drug development world is to move away from animal testing entirely. 

Clinical Trials Digital Health
Data Spotlight

Deals Of The Year 2022 Winners Revealed

For In Vivo's 15th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

Dealmaking Quarterly Statistics, Q4 2022

During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.

Financing Quarterly Statistics, Q4 2022

During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

The E in ESG: Philips Drives For Science-Based Targets In Carbon Zero Challenge

With a product mix that includes high energy consumption imaging, capital equipment and personal health care, Philips has a unique spectrum of challenges in driving low carbon health care. Nevertheless, it has set the bar high in environmental sustainability goals, and is pressing suppliers to follow its lead.

Leadership Sustainability

Backed By Big Names, Etherna Hopes To Disrupt mRNA Space

Belgian mRNA technologies firm Etherna, which is backed by high profile investors including former Bayer CEO Marijn Dekkers and Moderna co-founder Kenneth Chien, has reoriented its business model. Interim CEO Bernard Sagaert tells In Vivo how the firm hopes to deliver superior products for partners in the rapidly expanding RNA space.

Platform Technologies Commercial

Philips Healthcare: Targeting Healthtech Market Recovery Via Value Creation

Quality issues relating to a historical acquisition have held back Philips Healthcare’s financial performance in the post-COVID phase, while market competitors have been able to chart a less bumpy path through the tail end of the pandemic. All are facing supply chain and inflationary pressures.

Leadership Business Strategies

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Special Deliveries: Navigating The Growing Complexities Of Pharmaceutical Cold Chains

Pharmaceutical cold chain products are growing in number, complexity and reach. While life sciences organizations and their partners have been steadily investing in capabilities to effectively manufacture and distribute them, scaling them at the speed of innovation in an era of increasing regulatory and environmental requirements is more and more challenging.

Supply Chain Distribution

Looking Beyond The Deal In England

Agreement of deals that promise better value for money and enhanced patient access to new treatments has become routine in England, but are they delivering?

Deals Commercial

The E in ESG: Beware Green Claims That Might Backfire

Health care companies making carbon neutrality claims must tread a careful line while ensuring full accountability. CMS Vienna partner Gabriela Staber points to some of the risks businesses should be aware of when making sustainability claims.

Market Access Compliance

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Take Timely Steps To Alleviate Upcoming IVDR Compliance Woes

The transition periods for complying with the EU’s In Vitro diagnostics medical devices regulation might have been extended, but that does not change the scale of the compliance task at hand for manufacturers, says digital labeling provider Kallik.

Market Intelligence Regulation

Cross-Border M&A: 10 Key Trends To Watch In 2023

It will come as no surprise that cross-border M&A is impacted by the world we live in, with geopolitical tensions, rising inflation and interest rates, currency fluctuations, and increased regulatory scrutiny all playing their part in making deals more challenging to execute.

Business Strategies Companies

Deals In Depth: February 2023

Two $1bn+ alliances were penned in February. Topping the list was a potential $1.16bn deal between AstraZeneca and KYM Biosciences (a joint venture company of Keymed Biosciences and Lepu Biopharma, of which Keymed owns 70%). Under the exclusive global agreement, AstraZeneca will develop, manufacture and commercialize CMG901, a Phase I antibody drug conjugate for the treatment of Claudin 18.2-positive solid tumors including gastric cancers.

Deals Financing
UsernamePublicRestriction

Register